Condition (MeSH)
Granulomatous Disease, Chronic
ClinicalTrials.gov lists 78 trials for Granulomatous Disease, Chronic or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 30.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
78 of the 78 trials are tagged with Granulomatous Disease, Chronic itself; the rest are tagged with a narrower condition beneath it.
When did Granulomatous Disease, Chronic trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 5 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 31 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 12 trials still running at the 2026-10-09 snapshot; registered median of 69 months across 41 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Granulomatous Disease, Chronic trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 14 |
| Phase 1/2 | 23 |
| Phase 2 | 13 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 6 |
| Observational | 17 |
How many Granulomatous Disease, Chronic trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 11 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 6 |
| Completed | 30 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Granulomatous Disease, Chronic trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 30 |
| Ensoma | 2 |
| Bellicum Pharmaceuticals | 1 |
Which drugs are being tested for Granulomatous Disease, Chronic? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Busulfan | 10 |
| Cytoxan | 7 |
| Sirolimus | 5 |
| Melphalan | 2 |
| Plerixafor | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Alemtuzumab s.c. | 6 |
| SQ Fludarabine | 6 |
| Cyclosporine 0.05% | 3 |
| Total Body Irradiation | 3 |
| Hematopoietic Stem Cell Transplant | 2 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Granulomatous Disease, Chronic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Sepsis | 4 | 2 |
| Severe Acute GvHD | 3 | 1 |
| Cardiac arrest | 2 | 1 |
| Chronic graft versus host disease | 2 | 1 |
| Febrile neutropenia | 2 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Granulomatous Disease, Chronic? (90)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Interferon-gamma 1b-induced gene expression alters neutrophil function in patients with chronic granulomatous disease. | PloS one | 2025 | Yes |
| High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease. | Science translational medicine | 2024 | Yes |
| Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. | Blood | 2023 | Yes |
| Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease. | The Journal of allergy and clinical immunology | 2023 | Yes |
| In vivo interferon-gamma induced changes in gene expression dramatically alter neutrophil phenotype. | PloS one | 2022 | Yes |
Showing 5 of 90 publications.
Prevalence (81)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Chronic granulomatous disease | Prevalence at birth | 1-9 / 1 000 000 | United Kingdom | GB | Unspecified |
| Chronic granulomatous disease | Point prevalence | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Chronic granulomatous disease | Prevalence at birth | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Chronic granulomatous disease | Point prevalence | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Chronic granulomatous disease | Point prevalence | 1-9 / 1 000 000 | United Kingdom | GB | Unspecified |
Showing 5 of 81 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Chronic granulomatous disease | 379 | Exact | Orphadata Science knowledge files, Product 1 |
| Chronic granulomatous disease | 379 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.